Curcumin gets a makeover: new liposomal form tested in blood cancer
NCT ID NCT07456605
First seen Mar 10, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This early-phase study tests the safety of a new form of curcumin (liposomal curcumin) in people with multiple myeloma that has returned or stopped responding to treatment. About 20 participants will receive the drug, with doses increasing in later groups to find the highest safe dose. The goal is to see if this treatment can control the disease with manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network-Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.